Action - PARD

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

2,13

Prix Achat

0,00

Prix Vente

0,00

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

2,13

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

The Law Firm of Levi & Korsinsky, LLP Announces Investigation of Poniard Pharmaceuticals, Inc.

Levi & Korsinsky is investigating the Board of Directors of Poniard Pharmaceuticals, Inc. (“Poniard” or the “Company”) (NASDAQ:...

Law Office of Brodsky & Smith, LLC Announces Investigation of Poniard Pharmaceuticals, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Poniard...

Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility

Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility PR Newswire SAN...

Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market

Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market PR Newswire SOUTH SAN...

Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results

Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results - Conference Call Today at 4:30 p.m. Eastern Time - PR Newswire SOUTH SAN...

Poniard Pharmaceuticals Awarded $244,479 Grant Under Qualifying Therapeutic Discovery Project Program

Poniard Pharmaceuticals Awarded $244,479 Grant Under Qualifying Therapeutic Discovery Project Program PR Newswire SOUTH SAN FRANCISCO, Calif...

Poniard Pharmaceuticals to Host Third Quarter 2010 Financial Results Conference Call

Poniard Pharmaceuticals to Host Third Quarter 2010 Financial Results Conference Call PR Newswire SAN FRANCISCO, Nov. 3, 2010 SAN FRANCISCO, Nov...

Poniard Pharmaceuticals Reports Second Quarter 2010 Financial Results

Poniard Pharmaceuticals Reports Second Quarter 2010 Financial Results - Conference Call Today at 4:30 p.m. Eastern Time - -Principal Accounting...

Poniard Pharmaceuticals to Host Second Quarter 2010 Financial Results Conference Call

Poniard Pharmaceuticals to Host Second Quarter 2010 Financial Results Conference Call PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 2 SOUTH SAN...

Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price

Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price PR Newswire SOUTH SAN FRANCISCO, Calif., July 22 SOUTH SAN...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

PARD - Frequently Asked Questions (FAQ)

What is the current share price?

The current share price of is US$ 2,13

What is the 1 year trading range for share price?

has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
MASS908 Devices Inc	US$ 3,3101 (67,18%)	94,58M
PTIXProtagenic Therapeutics Inc	US$ 0,4269 (54,51%)	66,26M
FRGTFreight Technologies Inc	US$ 1,4505 (40,83%)	67,92M
JFINJiayin Group Inc	US$ 9,355 (32,32%)	648,15k
BTOGBit Origin Ltd	US$ 0,4169 (30,57%)	114,81M
TNYATenaya Therapeutics Inc	US$ 0,4319 (-54,39%)	12,34M
LGHLWLion Group Holding Ltd	US$ 0,0031 (-52,31%)	203,73k
AGHAureus Greenway Holdings Inc	US$ 1,1588 (-46,60%)	1,33M
STISolidion Technology Inc	US$ 0,16665 (-44,69%)	6,63M
JRVRJames River Group Holdings Ltd	US$ 3,105 (-36,63%)	2,09M
NVDANVIDIA Corporation	US$ 115,915 (1,63%)	236,79M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 11,43 (-9,79%)	125,2M
UOKAMDJM Ltd	US$ 0,1686 (12,40%)	120,4M
BTOGBit Origin Ltd	US$ 0,4169 (30,57%)	114,81M
MASS908 Devices Inc	US$ 3,3101 (67,18%)	94,58M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Poniard Pharmaceuticals, Inc. (MM) (PARD)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

PARD Dernières nouvelles

The Law Firm of Levi & Korsinsky, LLP Announces Investigation of Poniard Pharmaceuticals, Inc.

Law Office of Brodsky & Smith, LLC Announces Investigation of Poniard Pharmaceuticals, Inc.

Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility

Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market

Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results

Poniard Pharmaceuticals Awarded $244,479 Grant Under Qualifying Therapeutic Discovery Project Program

Poniard Pharmaceuticals to Host Third Quarter 2010 Financial Results Conference Call

Poniard Pharmaceuticals Reports Second Quarter 2010 Financial Results

Poniard Pharmaceuticals to Host Second Quarter 2010 Financial Results Conference Call

Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price

PARD - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Poniard Pharmaceuticals, Inc. (MM) (PARD) Cours

Poniard Pharmaceuticals, Inc. (MM) (PARD)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

PARD Dernières nouvelles

The Law Firm of Levi & Korsinsky, LLP Announces Investigation of Poniard Pharmaceuticals, Inc.

Law Office of Brodsky & Smith, LLC Announces Investigation of Poniard Pharmaceuticals, Inc.

Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility

Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market

Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results

Poniard Pharmaceuticals Awarded $244,479 Grant Under Qualifying Therapeutic Discovery Project Program

Poniard Pharmaceuticals to Host Third Quarter 2010 Financial Results Conference Call

Poniard Pharmaceuticals Reports Second Quarter 2010 Financial Results

Poniard Pharmaceuticals to Host Second Quarter 2010 Financial Results Conference Call

Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price

PARD - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS